文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

不同含多黏菌素方案治疗多重耐药革兰阴性菌肺炎的疗效与安全性:系统评价与网状Meta分析

Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and network meta-analysis.
PubMed 文献 · Crit Care · 2024-07-14
一句话结论网状Meta分析提示,静脉联合吸入多黏菌素方案治疗多重耐药革兰阴性菌肺炎可能最有效,总体死亡率低于静脉方案,微生物清除率高于吸入方案。

本研究系统检索九个数据库,纳入19项观察性研究和3项随机对照试验(共3318例患者),比较静脉(IV)、吸入(IH)及静脉联合吸入(IV+IH)三种含多黏菌素方案治疗多重耐药革兰阴性菌肺炎的疗效与安全性。主要终点为总体死亡率,次要终点包括微生物清除率、临床成功率、急性肾损伤及支气管痉挛发生率。网状Meta分析显示,IV+IH方案较IV方案显著降低总体死亡率(OR 0.67;95%CI 0.50-0.88)、提高临床成功率(OR 1.90;95%CI 1.20-3.00)和微生物清除率(OR 2.70;95%CI 1.90-3.90),且微生物清除率显著优于IH方案(OR 2.30;95%CI 1.30-4.20)。IH方案较IV+IH和IV方案显著减少急性肾损伤。作者认为IV+IH方案可能最有效,IH方案可能优于IV方案。

要点

  • 纳入19项观察性研究和3项RCT共3318例患者,6项高偏倚风险研究被排除在主要分析之外。
  • 网状Meta分析显示,IV+IH方案较IV方案显著降低总体死亡率(OR 0.67;95%CI 0.50-0.88)。
  • IV+IH方案较IV方案显著提高临床成功率(OR 1.90;95%CI 1.20-3.00)和微生物清除率(OR 2.70;95%CI 1.90-3.90)。
  • IV+IH方案较IH方案微生物清除率显著更高(OR 2.30;95%CI 1.30-4.20)。
  • IH方案较IV+IH和IV方案显著减少急性肾损伤,但总体死亡率降低无统计学意义。

适用人群与场景

  • 多重耐药革兰阴性菌(MDR-GNB)肺炎患者,来自纳入的19项观察性研究和3项随机对照试验,共3318例。

处置流程与药物剂量

  • 比较三种含多黏菌素给药方案:静脉(IV)方案、吸入(IH)方案、静脉联合吸入(IV+IH)方案。

研究设计与关键结果

  • 研究类型:系统评价与网状Meta分析,纳入19项观察性研究和3项随机对照试验(RCT),共3318例患者;6项高偏倚风险研究被排除在主要分析之外;采用Cochrane风险偏倚工具第2版和ROBINS-I评估偏倚风险。
  • 主要终点:IV+IH方案较IV方案显著降低总体死亡率(OR 0.67;95%CI 0.50-0.88)。
  • 次要终点:IV+IH方案较IV方案显著提高临床成功率(OR 1.90;95%CI 1.20-3.00)和微生物清除率(OR 2.70;95%CI 1.90-3.90)。
  • IV+IH方案较IH方案微生物清除率显著更高(OR 2.30;95%CI 1.30-4.20)。
  • IH方案较IV+IH和IV方案显著减少急性肾损伤。
  • 配对Meta分析中,IV+IH方案较IV方案总体死亡率显著降低,IH方案与IV方案比较无统计学显著差异。

证据类型、等级与局限

  • 证据类型:系统评价与网状Meta分析,纳入19项观察性研究和3项随机对照试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在三种给药方案中,IV+IH含多黏菌素方案可能对治疗MDR-GNB肺炎最有效,较IV方案显著降低总体死亡率,较IH方案显著提高微生物清除率。
  • 作者认为,IH方案可能优于IV方案,因其显著降低急性肾损伤发生率,尽管总体死亡率降低无统计学意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal administration of polymyxins for treating multidrug-resistant gram-negative bacterial (MDR-GNB) pneumonia remains unclear. This study aimed to systematically assess the efficacy and safety of three polymyxin-containing regimens by conducting a comprehensive network meta-analysis.

METHODS: We comprehensively searched nine databases. Overall mortality was the primary outcome, whereas the secondary outcomes encompassed microbial eradication rate, clinical success, acute kidney injury, and incidence of bronchospasm. Extracted study data were analyzed by pairwise and network meta-analyses. Version 2 of the Cochrane risk-of-bias tool and the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) assessment tool were used to assess the risk of bias in randomized trials and cohort studies, respectively.

RESULTS: This study included 19 observational studies and 3 randomized controlled trials (RCTs), encompassing 3318 patients. Six studies with high risk of bias were excluded from the primary analysis. In the pairwise meta-analysis, compared to the intravenous (IV) polymyxin-containing regimen, the intravenous plus inhaled (IV + IH) polymyxin-containing regimen showed a significant decrease in overall mortality, while no statistically significant difference was found in the inhaled (IH) polymyxin-containing regimen. The network meta-analysis indicated that the IV + IH polymyxin-containing regimen had significantly lower overall mortality (OR 0.67; 95% confidence interval [CI] 0.50-0.88), higher clinical success rate (OR 1.90; 95% CI 1.20-3.00), better microbial eradication rate (OR 2.70; 95% CI 1.90-3.90) than the IV polymyxin-containing regimen, and significantly better microbial eradication rate when compared with the IH polymyxin-containing regimen (OR 2.30; 95% CI 1.30-4.20). Furthermore, compared with IV + IH and IV polymyxin-containing regimens, the IH polymyxin-containing regimen showed a significant reduction in acute kidney injury.

CONCLUSIONS: Our study indicates that among the three administration regimens, the IV + IH polymyxin-containing regimen may be the most effective for treating MDR-GNB pneumonia, with a significantly lower overall mortality compared to the IV regimen and a considerably higher microbial eradication rate compared to the IH regimen. The IH regimen may be considered superior to the IV regimen due to its substantially lower incidence of acute kidney injury, even though the reduction in overall mortality was not significant.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Zhou Y, Wang G, Zhao Y, et al. Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and network meta-analysis. Crit Care. 2024. PMID: 39004760. doi:10.1186/s13054-024-05031-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。